CDK4 and breast carcinoma: Importantly, it was previously shown that breast cancer cells resistant to CDK4/6 inhibitors can be successfully eradicated using drugs that target the downstream signalling of the receptor tyrosine kinases, such as lucitanib (FGFR) and alpelisib (p110α-selective inhibitors of PI3K) [61,62,63].